Bristol/Pfizer's Apixaban Gets A Chance At The Inside Track
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has agreed to review the anticoagulant based on the results of the AVERROES trial, offering a potentially faster route to market.